Basic Information
| LncRNA/CircRNA Name | LINC-ROR |
| Synonyms | LINC-ROR, ROR, lincRNA-RoR |
| Region | GRCh38_18:57054558-57072119 |
| Ensemble | ENSG00000258609 |
| Refseq | NR_048536 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR etc. |
| Sample | Triple-negative breast cancer tissues, cell line (HEK293T, MCF-10A, MCF-7, BT474, MDA-MB-453 and MDA-MB-231) |
| Expression Pattern | down-regulated |
| Function Description | lincRNA-ROR was upregulated in TNBC cell lines and tissue samples.The aberrant expression of lincRNA-ROR was shown to increase invasion and metastasis in MDA-MB-231 and loss of function by siRNA reverse these process.Furthermore, lincRNA-ROR functions as a competing endogenous RNAs (ceRNA) which sponges miR-145 and therefore upregulate the expression of Mucin1 (MUC1).Studies showed that downregulated SPRY4-IT1 could facilitate bladder cancer cell apoptosis via acting as a ceRNA for miR-101-3p. |
| Pubmed ID | 29673594 |
| Year | 2018 |
| Title | LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1. |
External Links
| Links for LINC-ROR | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |